Sunday, May 22, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

New radio-labeled molecule may allow a non-invasive approach to monitor inflammation in real time

by Medical Finance
in News
NYBC discovers novel small-molecule pancoronavirus fusion inhibitors
9
SHARES
103
VIEWS
Share on FacebookShare on Twitter

Researchers at The University of Texas MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively reacting with certain high-energy radicals that are characteristic of innate immune activity, which may allow a non-invasive approach to monitor inflammation in real time by positron emission tomography (PET) imaging.

The preclinical study, published today in Nature Biotechnology, takes advantage of new chemistry techniques to synthesize 4-[18F]Fluoro-1-Naphthol ([18F]4FN) as a novel reporter of myeloperoxidase (MPO) activity – a key enzyme active in the innate immune response. The molecule may be able to pinpoint areas of inflammation in a variety of clinical settings, such as inflammatory diseases, infections and immunotherapy-related side effects.

“There has been a long-standing interest in imaging inflammation and redox in general, but most current approaches generate high levels of background noise from biological processes that generate lower-energy radicals,” said corresponding author David Piwnica-Worms, M.D., Ph.D., chair of Cancer Systems Imaging. “Our molecule is tuned toward inflammation mediated by high-energy radicals, offering the potential to selectively monitor activation of innate immunity.”

The innate immune response is the body’s first line of defense against invading pathogens. In contrast to the adaptive immune response, innate immunity is nonspecific and acts broadly against infections or foreign agents. Innate immunity is largely driven by myeloid cells, including neutrophils, macrophages and natural killer (NK) cells.

Myeloperoxidase is a highly conserved feature of the innate immune response across myeloid cells. This proinflammatory enzyme is activated by hydrogen peroxide to produce a variety of high-energy radicals that are used to eliminate pathogens.

Co-led by Federica Pisaneschi, Ph.D., assistant professor, and Seth T. Gammon, Ph.D., associate professor of Cancer Systems Imaging, the research team focused on MPO activity to develop a redox-tuned reporter specific to innate immune activity. Using newly developed chemistry techniques, the team was able to synthesize [18F]4FN as a labeled molecule to selectively bind nearby proteins and cells when [18F]4FN has been oxidized by MPO plus hydrogen peroxide, but not hydrogen peroxide alone.

The researchers evaluated the potential uses of [18F]4FN as an in vivo PET imaging tool in several laboratory models of inflammation. The molecule was able to successfully highlight inflammation from acute toxic shock, arthritis and contact dermatitis, ailments known to be mediated by activation of innate immunity. In addition, their results suggest [18F]4FN is a more specific and robust reporter of inflammation than other clinically utilized PET imaging agents, such as fluorodeoxyglucose ([18F]FDG).

“We need to verify this PET imaging agent in clinical studies, but it certainly has the potential for broad applications that could benefit patients across all kinds of diseases and clinical scenarios,” Piwnica-Worms said. “A tool like this could be used to identify multi-focal hotspots of inflammation, allowing physicians to intervene before disease progression or to follow the resolution of symptoms during therapy.”

The research team is in discussions with clinical collaborators to test specific applications of [18F]4FN. An initial study, now under Food and Drug Administration review for Investigational New Drug registration and Institutional Review Board approval, will evaluate [18F]4FN as an early biomarker of immune-related adverse events in patients being treated with immune checkpoint inhibitors.

Source:

University of Texas M. D. Anderson Cancer Center

Journal reference:

Pisaneschi, F., et al. (2022) Imaging of innate immunity activation in vivo with a redox-tuned PET reporter. Nature Biotechnology. doi.org/10.1038/s41587-021-01169-y.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

New mathematical model can calculate the risk of resistance evolution for drug pairs

Antibiotic treatment after birth affects a newborn’s gut microbiome

by Medical Finance
May 21, 2022
0

Treating babies with antibiotics in the first week of life is linked with a decrease in healthy bacteria necessary amongst...

Scientists identify a new switch for controlling motor proteins

Study identifies a protein complex critical for regulating apoptosis and necroptosis

by Medical Finance
May 21, 2022
0

Cell death plays an important role in normal human development and health but requires tightly orchestrated balance to avert disease....

Scientists unravel how blood cells mount the first line of defense against viruses

Structure of protein that can pump toxic molecules out of bacterial cells revealed

by Medical Finance
May 21, 2022
0

MIT chemists have discovered the structure of a protein that can pump toxic molecules out of bacterial cells. Proteins similar...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Novel platform can become a potential approach for personalized cancer treatments

by Medical Finance
May 21, 2022
0

Killing cancer cells without affecting surrounding normal cells is the most desirable approach for targeted cancer therapy. However, it cannot...

Specialized subset of CD4+ T cells jump into action early during an infection, study shows

Specialized subset of CD4+ T cells jump into action early during an infection, study shows

by Medical Finance
May 21, 2022
0

Every kind of T cell has a job to do. A healthy immune system makes sure no T cell oversteps....

New evidence supports the link between growth-induced respiratory stress and fish reproduction

Study uncovers clue to why pigs don’t get sick when exposed to COVID-19

by Medical Finance
May 21, 2022
0

Iowa State University scientists may have uncovered an important clue that sheds light on why pigs don't get sick when...

Next Post
Scientists unravel how blood cells mount the first line of defense against viruses

Genome research explains why oats could be suitable for most people with celiac disease

Swapping single food item for a more planet-friendly alternative could reduce diet’s carbon footprint

First large-scale estimate of live microbes consumed by Americans daily

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • By Phonlamai Photo 034cc2a48c3c4bd2a57e29e397b7210a 620x480
    FUJIFILM Healthcare Europe presents ECHELON™ Smart Plus™
  • Study: Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients. Image Credit: Viacheslav Lopatin/Shutterstock
    Evaluating immune protection after third and fourth doses of homologous and heterologous SARS-CoV-2 vaccines among kidney transplant recipients
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply